Topic:

Pipeline

Latest Headlines

Latest Headlines

Bristol-Myers, Celgene pair an immuno-oncology star with a rising chemotherapy

Bristol-Myers Squibb and Celgene are joining forces on a cancer combination treatment, testing the former's highly anticipated immunotherapy in tandem with an on-the-market chemo drug against a host of tumor targets.

MorphoSys bets on Emergent BioSolutions' cancer contender in $183M deal

German drug developer MorphoSys is pairing up with Emergent BioSolutions to get its hands on an early-stage prostate cancer treatment, signing a deal worth up to $183 million for a promising antibody.

Amicus sets sights on approval as rare disease pill clears Phase III

Amicus Therapeutics has come a long way in two years, shaking off a clinical misstep on the way to a second Phase III success for its rare disease treatment. Now the biotech is preparing to make its case to regulators, hoping to win approval for a new approach to Fabry disease.

Merck KGaA's cancer vaccine endures another clinical failure

Tecemotide, Merck KGaA's 9-lived cancer vaccine, has flunked another clinical trial, missing its main goal in a Japanese study and casting further doubts on the program's future.

Amgen successfully hits another PhIII goal line with kidney dialysis drug

Amgen successfully wrapped its second Phase III study for AMG416, its late-stage drug for secondary hyperparathyroidism that's now one final study away from a prospective regulatory filing.

Pfizer hands in an early application for the blockbuster contender palbociclib

As expected, Pfizer has submitted an early FDA application for palbociclib, beating a quick path to market with a breakthrough breast cancer treatment that could peak at nearly $3 billion a year.

Novo chief Sorensen preps for showdown as Lilly's dulaglutide nears diabetes market

The executive team here at the rapidly expanding headquarters of Novo Nordisk doesn't pull many punches. CEO Lars Rebien S ø rensen is a competitive sort who tends to be blunt, aggressive and forward-thinking; projecting a confident attitude that is reflected by the rest of the execs and right down the line to 40,000 rank-and-file employees around the world.

Teva tries laquinimod in Huntington's after repeated MS woes

Teva Pharmaceutical is rolling its troubled CNS drug laquinimod into a mid-stage study in Huntington's disease, looking to expand the potential of a treatment marked by clinical and regulatory setbacks.

AstraZeneca squares off against Roche in blockbuster PhIII asthma showdown

AstraZeneca has launched a Phase III test of its targeted IL-13 asthma drug tralokinumab, beefing up its late-stage pipeline for respiratory diseases and squaring off against some major league competition now in the clinic.

Rigel endures another clinical setback as eye drug flunks Phase II

Rigel Pharmaceuticals' just got a little thinner, as another failed clinical trial has dimmed its hopes in dry eye disease, the latest in a string of missteps for the biotech.